New stock news | Hansen Ai Tai goes through a hearing at the Hong Kong Stock Exchange, generating operating losses during the previous record period.

According to the Zhixingtong Finance APP, as disclosed by the Hong Kong Stock Exchange on December 3, HanSi AiTai Biomedical Technology (Wuhan) Co., Ltd. (referred to as HanSi AiTai) has passed the listing hearing on the main board of the Hong Kong Stock Exchange, with CICC International acting as its exclusive sponsor. According to the prospectus, HanSi AiTai is a biotechnology company with independent professional technology and experience in the fields of structural biology, translational medicine, and clinical development. Since 2016, the company has developed a product pipeline, including a core product and nine other candidate products, namely: (i) three clinical-stage candidate drugs for oncology, including the company's core product HX009 and main products HX301 and HX044; (ii) seven preclinical-stage candidate drugs, including antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies for the autoimmune and oncology markets. The company has also developed HX008, which has been transferred to a biopharmaceutical company specializing in oncology therapy.